Evidence map›Paper›PMID 39039304›Full record

ReviewPurinergic signalling2025

Role of the P2X7 receptor in breast cancer progression.

Yanan Du, Yahui Cao, Wei Song, Xin Wang, Qingqing Yu, Xiaoxiang Peng, Ronglan Zhao

Abstract readReview
In one paragraph

Review in Purinergic signalling, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Therapeutic Significance of NLRP3 Inflammasome in Cancer: Friend or Foe?International journal of molecular sciences · 2024
    Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Yanan DuSchool of Medical Laboratory, Shandong Second Medical University, Shandong, 261053, China.
Yahui CaoSchool of Medical Laboratory, Shandong Second Medical University, Shandong, 261053, China.
Wei SongSchool of Medical Laboratory, Shandong Second Medical University, Shandong, 261053, China.
Xin WangSchool of Medical Laboratory, Shandong Second Medical University, Shandong, 261053, China.
Qingqing YuSchool of Medical Laboratory, Shandong Second Medical University, Shandong, 261053, China.
Xiaoxiang PengSchool of Medical Laboratory, Shandong Second Medical University, Shandong, 261053, China. pxx74@sina.com.
Ronglan ZhaoSchool of Medical Laboratory, Shandong Second Medical University, Shandong, 261053, China. zhaoronglan76@sina.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Breast cancer is a common malignant tumor, whose incidence is increasing year by year, and it has become the malignant tumor with the highest incidence rate in women. Purine ligand-gated ion channel 7 receptor (P2X7R) is a cation channel receptor with Adenosine triphosphate ( ATP) as a ligand, which is widely distributed in cells and tissues, and is closely related to tumorigenesis and progression. P2X7R plays an important role in cancer by interacting with ATP. Studies have shown that P2X7R is up-regulated in breast cancer and can promote tumor invasion and metastasis by activating the protein kinase B (AKT) signaling pathway, promoting epithelial-mesenchymal transition (EMT), controlling the generation of extracellular vesicle (EV), and regulating the expression of the inflammatory protein cyclooxygenase 2 (COX-2). Furthermore, P2X7R was proven to play an essential role in the proliferation and apoptosis of breast cancer cells. Recently, inhibitors targeting P2X7R have been found to inhibit the progression of breast cancer. Natural P2X7R antagonists, such as rhodopsin, and the isoquinoline alkaloid berberine, have also been shown to be effective in inhibiting breast cancer progression. In this article, we review the research progress of P2X7R and breast cancer intending to provide new targets and directions for breast cancer treatment.

Indexed as

Breast NeoplasmsReceptors, Purinergic P2X7AnimalsDisease ProgressionFemaleHumansPurinergic P2X Receptor AntagonistsSignal TransductionPurinergic P2X Receptor AntagonistsReceptors, Purinergic P2X7Breast cancerP2X7RP2X7R antagonistTumor progression

Identifiers

PMID39039304
PMCPMC12454856

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.